166047-75-2

Basic information

• Product Name: Propanoic acid, 3,3'-[[2-amino-2-[(3-methoxy-3-oxopropoxy)methyl]-1,3-propanediyl]bis( oxy)]bis-, dimethyl ester
• CAS NO: 166047-75-2
• Molecular Formula: C16H29NO9
• Molecular Weight: 379.408
• Mol File: 166047-75-2.mol
• Article Data: 9

Chemical Properties

• CAS DataBase Reference: Propanoic acid, 3,3'-[[2-amino-2-[(3-methoxy-3-oxopropoxy)methyl]-1,3-propanediyl]bis( oxy)]bis-, dimethyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: Propanoic acid, 3,3'-[[2-amino-2-[(3-methoxy-3-oxopropoxy)methyl]-1,3-propanediyl]bis( oxy)]bis-, dimethyl ester(166047-75-2)
• EPA Substance Registry System: Propanoic acid, 3,3'-[[2-amino-2-[(3-methoxy-3-oxopropoxy)methyl]-1,3-propanediyl]bis( oxy)]bis-, dimethyl ester(166047-75-2)

Safety Data

• Hazardous Substances Data: 166047-75-2(Hazardous Substances Data)

Upstream product

• 67-56-1 methanol 
• 132491-89-5 tris(cyanoethoxymethyl)aminomethane 
• 566168-32-9 [2-(2-cyano-ethoxy)-1,1-bis-(2-cyano-ethoxymethyl)-ethyl]-carbamic acid tert-butyl ester 

Downstream Products

• 220886-02-2 N-(N-benzyloxycarbonyl-glycinyl)-tris(carboxyethoxymethyl)aminomethane 
• 200133-20-6 di-tert-butyl 3,3'-((2-(((benzyloxy)carbonyl)amino)-2-((3-(tert-butoxy)-3-oxopropoxy)methyl)propane-1,3-diyl)bis(oxy))dipropionate 
• 200133-16-0 benzyl N-tris[(2-carboxyethyloxy)methyl]methylcarbamate 
• 175724-30-8 tris{[2-(tert-butoxycarbonyl)ethoxy]methyl}methylamine 
• 200133-17-1 benzyl N-tris[2-{[({tris[[2-(methoxycarbonyl)ethoxy]methyl]methyl}amino)carbonyl]ethoxy}methyl]methylcarbamate 
• 200133-15-9 N-(Benzyloxycarbonyl)-tris[((methoxycarbonyl)ethoxy)methyl]aminomethane 

Relevant articles and documents

A dendritic DPA annihilator—syntheses, photophysical properties and application for co-assembling enhanced triplet-triplet annihilation upconversion

A dendritic annihilator D-2 containing 18 peripherical methyl ester units was synthesized by attaching the branches on the phenyl unit of 9,10-diphenylanthracene (DPA). The absorption and emission spectra of D-2 are very similar to the unbranched DPA diacid 5 and the lower branched homolog D-1, while the fluorescence quantum yield increased with the degrees of the branching and was determined to be 86.9percent for D-2 in MeOH. D-2 was used as the annihilator for triplet-triplet annihilation upconversion with a Schiff-base Pt(II) complex serving as the sensitizer. It was found that D-2 showed very weak UC emission in MeOH with a UC quantum yield of only 1.4percent. Interestingly, the UC emission intensity increased significantly by adding different amounts of water in MeOH, the UC intensity was enhanced by more than 9 fold by adding 40percent water into MeOH, and the UC quantum yield was determined to be 10.2percent in MeOH with 40percent water. A mechanism for the enhancing of UC emission was proposed: When in MeOH, the large molecule size of the dendrimer limited the movability of the acceptor, and the shielding effect of the dendritic branches on the DPA core limited the intimate contacts among DPA cores or between DPA core and the sensitizer. When the water was added, D-2 aggregated to nanoparticles with internal hydrophobic cavities induced by the hydrophobic effect and π-π stacking of DPA core, the sensitizer Pt-1 was captured in the internal hydrophobic cavities, and thus, both the TTET and TTA processes were greatly accelerated which attributed to the enhanced TTA-UC.

Polyanion inhibitors of human immunodeficiency virus. Part IV. - Polymerized anionic surfactants : Influence of the density and distribution of anionic groups on the antiviral activity

The synthesis of a series of new polyanions, via γ-polymerization, of ω-unsaturated multi-charged anionic surfactants, has been realized. These polyanions were evaluated for their activity against HIV-1. All tested compounds proved active without presenting toxicity to the host cells (CEM-4 or MT-4).

ENGINEERED ANTIBODIES AS MOLECULAR DEGRADERS THROUGH CELLULAR RECEPTORS

The present disclosure provides, in one aspect, bifunctional compounds that can be used to promote or enhance degradation of certain circulating proteins. In certain embodiments, the circulating protein mediates a disease and/or disorder in a subject, and treatment or management of the disease and/or disorder requires degradation, removal, or reduction in concentration of the circulating protein in the subject. Thus, in certain embodiments, administration of a compound of the disclosure to the subject removes or reduces the circulation concentration of the circulating protein, thus treating, ameliorating, or preventing the disease and/or disorder.

BIFUNCTIONAL SMALL MOLECULES TO TARGET THE SELECTIVE DEGRADATION OF CIRCULATING PROTEINS

The present invention is directed to bifunctional small molecules which contain a circulating protein binding moiety (CPBM) linked through a linker group to a cellular receptor binding moiety (CRBM) which is a membrane receptor of degrading cell such as a hepatocyte or other degrading cell. In embodiments, the (CRBM) is a moiety which binds to asialoglycoprotein receptor (an asialoglycoprotein receptor binding moiety, or ASGPRBM) of a hepatocyte. In additional embodiments, the (CRBM) is a moiety which binds to a receptor of other cells which can degrade proteins, such as a LRP1, LDLR, FcyRI, FcRN, Transferrin or Macrophage Scavenger receptor. Pharmaceutical compositions based upon these bifunctional small molecules represent an additional aspect of the present invention. These compounds and/or compositions may be used to treat disease states and conditions by removing circulating proteins through degradation in the hepatocytes or macrophages of a patient or subject in need of therapy. Methods of treating disease states and/or conditions in which circulating proteins are associated with the disease state and/or condition are also described herein.